Get the Daily Brief

All action, no filler. BioBriefs delivers the industry’s 10 must-know updates, every morning.

Latest Biotech News

Regulatory approval – mRNA flu vaccine

August 11, 2026

The FDA approved Moderna’s seasonal influenza mRNA vaccine mRNA-1010 (mFLUSIVA), marking the first approved flu shot built on an mRNA platform. The decision followed a unanimous VRBPAC vote,...

Biopharma reshoring – BMS manufacturing campus

August 11, 2026

Bristol Myers Squibb selected Houston for a new $2.3 billion multi-modal manufacturing campus designed to support drug product and finished goods from late development through launch. The site...

Clinical setback – cystic fibrosis add-on failure

August 11, 2026

Sionna Therapeutics said its cystic fibrosis strategy hit a wall in a Phase 2 trial, reporting that SION-719 did not provide additive benefit when combined with Vertex’s Trikafta. The company now...

Rare disease M&A – Jazz acquires Actio

August 11, 2026

Jazz Pharmaceuticals agreed to acquire Actio Biosciences in a deal valued at just over $1.3 billion, consisting of $820 million upfront plus up to $500 million in milestone payments tied to...

Rare blood cancer trial win – Silence Phase 2

August 11, 2026

Silence Therapeutics reported Phase 2 success for its siRNA therapy divesiran in polycythemia vera, hitting the trial’s primary endpoint in the 48-person study. Silence said 88% of patients...

Cell therapy decision support – AML transplant model

August 11, 2026

A new gene-expression risk model is being used to personalize allogeneic stem cell transplant decisions for children with AML, aiming to refine who benefits most from allo-HSCT. The approach...

Companion diagnostics – Labcorp FDA approval

August 11, 2026

The FDA approved Labcorp’s PGDx elio tissue complete as a companion diagnostic for detecting BRAF V600E and V600K mutations in melanoma. Labcorp said the approval enables patient selection for...

Weight management access – Medicare GLP-1 Bridge pricing

August 11, 2026

CMS’s Medicare GLP-1 Bridge program is reshaping weight management pricing by setting a flat $50 monthly copay point for eligible beneficiaries through December 31, 2027. The program runs outside...

Oncology transplant/cancer diagnostics – Natera MRD and early cancer push

August 11, 2026

Natera said it is expanding beyond its existing MRD footprint after a series of regulatory milestones for Signatera. The company received FDA approval for companion diagnostic use in...

Drug safety and clinical trial operations – ITTs under China tightening

August 11, 2026

China is tightening oversight of investigator-initiated trials (ITTs), a model that has helped accelerate trial starts but has increasingly drawn scrutiny. A STAT+ report said new enforcement is...

FDA approvals

August 11, 2026

The FDA approved Moderna’s seasonal influenza mRNA vaccine (mRNA-1010, mFLUSIVA) for adults, marking the first FDA clearance for an mRNA flu shot in the U.S. The approval followed a unanimous...

Company earnings & platform expansion

August 11, 2026

Alamar Biosciences reported a sharp revenue rebound in its first full quarter as a public company, alongside an expansion of a large-scale plasma proteomics collaboration tied to Alzheimer’s. In...

Clinical trial failures in competitive areas (cystic fibrosis)

August 11, 2026

Sionna Therapeutics ended its cystic fibrosis add-on strategy after a Phase 2 trial failed to show benefit when paired with Vertex’s Trikafta. In the Precision CF study, Sionna’s SION-719 plus...

Clinical trial success driving advancement (rare blood cancer)

August 11, 2026

Silence Therapeutics announced Phase 2 success for divesiran in polycythemia vera, setting up a move into Phase 3 for the gene-silencing therapy. In the 48-patient trial, Silence said 88% of...

Dealmaking & expansion (epilepsy)

August 11, 2026

Jazz Pharmaceuticals agreed to acquire Actio Biosciences in a deal that could total more than $1.3 billion, adding a clinical-stage precision therapy targeting KCNT1-related epilepsy. Under the...

Regulatory action & trial acceleration policy

August 11, 2026

U.S. lawmakers are advancing a proposed trial-reform approach that would embed clinical research into routine care to speed up first-in-human study starts. The effort, linked to a “Hauchincloss”...

Regulatory pipeline for diagnostics (FDA clearance)

August 11, 2026

Qiagen received FDA clearance for a gram-positive bacterial and fungal bloodstream infection test that runs on the QiaStat-Dx platform, extending the company’s BCID assay menu in the U.S. The...

Oncology diagnostics & companion testing (FDA approval)

August 11, 2026

Labcorp said the FDA approved PGDx elio tissue complete as a companion diagnostic for BRAF V600E and V600K mutations in melanoma, expanding access to mutation testing that guides targeted...

Radiopharmaceuticals: safety/manufacturing setbacks

August 11, 2026

FDA rejected ITM Isotope Technologies Munich’s radiopharmaceutical therapy candidate for neuroendocrine tumors after manufacturing problems surfaced during review. The decision delays a potential...

Immunotherapy trial momentum (Phase 2 data)

August 11, 2026

AbCellera reported Phase 2 results for a NK3R-targeting therapy in vasomotor symptoms, positioning its program to compete for share in the hot-flash treatment market. The company’s shares rose...